To determine whether an LRP-1 agonist, SP16, might prevent the depletion of CD4+ T cells, animals were started on SP16 treatment during late-stage NAFLD, after 28 weeks of a WD. The gene discussed is CD4; the disease is metabolic dysfunction-associated steatotic liver disease.